These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 8729949)

  • 41. A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent breast cancer.
    Adachi I; Watanabe T; Takashima S; Narabayashi M; Horikoshi N; Aoyama H; Taguchi T
    Br J Cancer; 1996 Jan; 73(2):210-6. PubMed ID: 8546908
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Activity and safety of epirubicin plus paclitaxel in advanced breast cancer.
    Conte PF; Michelotti A; Baldini E; Tibaldi C; DaPrato M; Salvadori B; Giannessi PG; Gentile A; Biadi O; Mariani M
    Semin Oncol; 1996 Feb; 23(1 Suppl 1):28-32. PubMed ID: 8629033
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer.
    Reichman BS; Seidman AD; Crown JP; Heelan R; Hakes TB; Lebwohl DE; Gilewski TA; Surbone A; Currie V; Hudis CA
    J Clin Oncol; 1993 Oct; 11(10):1943-51. PubMed ID: 7691998
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Doxorubicin and paclitaxel (sequential combination) in the treatment of advanced breast cancer.
    Amadori D; Frassineti GL; Zoli W; Milandri C; Serra P; Tienghi A; Ravaioli A; Gentile A; Salzano E
    Oncology (Williston Park); 1997 Apr; 11(4 Suppl 3):30-3. PubMed ID: 9144688
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life.
    Palumbo R; Sottotetti F; Trifirò G; Piazza E; Ferzi A; Gambaro A; Spinapolice EG; Pozzi E; Tagliaferri B; Teragni C; Bernardo A
    Drug Des Devel Ther; 2015; 9():2189-99. PubMed ID: 25931813
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Paclitaxel and carboplatin as first-line chemotherapy for advanced breast cancer.
    Fountzilas G; Athanassiades A; Papadimitriou V; Dimopoulos MA; Bafaloukos D; Aravantinos G; Nicolaides C; Kalofonos H; Papakostas P; Xiros N; Razi E
    Oncology (Williston Park); 1998 Jan; 12(1 Suppl 1):45-8. PubMed ID: 9516604
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Doxorubicin and paclitaxel, a highly active combination in the treatment of metastatic breast cancer.
    Dombernowsky P; Gehl J; Boesgaard M; Paaske T; Jensen BV
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):23-7. PubMed ID: 8893895
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Paclitaxel has moderate activity in squamous cervix cancer. A Gynecologic Oncology Group study.
    McGuire WP; Blessing JA; Moore D; Lentz SS; Photopulos G
    J Clin Oncol; 1996 Mar; 14(3):792-5. PubMed ID: 8622025
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Docetaxel as neoadjuvant chemotherapy in patients with stage III breast cancer.
    Gradishar WJ
    Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):15-8. PubMed ID: 9364536
    [TBL] [Abstract][Full Text] [Related]  

  • 50. High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibody.
    Richman CM; Denardo SJ; O'Donnell RT; Yuan A; Shen S; Goldstein DS; Tuscano JM; Wun T; Chew HK; Lara PN; Kukis DL; Natarajan A; Meares CF; Lamborn KR; DeNardo GL
    Clin Cancer Res; 2005 Aug; 11(16):5920-7. PubMed ID: 16115934
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phase II study of paclitaxel and epirubicin as first-line therapy in patients with metastatic breast cancer.
    Lück HJ; Thomssen C; du Bois A; Untch M; Lisboa B; Köhler G; Diergarten K
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-35-S17-39. PubMed ID: 9374090
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer.
    Seidman AD; Tiersten A; Hudis C; Gollub M; Barrett S; Yao TJ; Lepore J; Gilewski T; Currie V; Crown J
    J Clin Oncol; 1995 Oct; 13(10):2575-81. PubMed ID: 7595709
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A randomized study of paclitaxel versus cyclophosphamide/methotrexate/5-fluorouracil/prednisone in previously untreated patients with advanced breast cancer: preliminary results. Taxol Investigational Trials Group, Australia/New Zealand.
    Bishop JF; Dewar J; Toner G; Tattersall MH; Olver I; Ackland S; Kennedy I; Goldstein D; Gurney H; Walpole E; Levi J; Stephenson J
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-5-S17-9. PubMed ID: 9374084
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phase I trial of paclitaxel, carboplatin, and methotrexate with granulocyte colony-stimulating factor and leucovorin in advanced transitional cell carcinoma.
    Edelman MJ; Meyers FJ; Houston J; Lauder I
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-68-S15-71. PubMed ID: 9346226
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Phase II study of weekly paclitaxel for advanced or metastatic breast cancer in Japan.
    Horiguchi J; Rai Y; Tamura K; Taki T; Hisamatsu K; Ito Y; Seriu T; Tajima T
    Anticancer Res; 2009 Feb; 29(2):625-30. PubMed ID: 19331212
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Paclitaxel plus doxorubicin in metastatic breast Ca: the Milan experience.
    Gianni L
    Oncology (Williston Park); 1998 Jan; 12(1 Suppl 1):13-5. PubMed ID: 9516596
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Paclitaxel and epirubicin as first-line therapy for patients with metastatic breast cancer.
    Lück HJ; Du Bois A; Thomssen C; Lisboa B; Untch M; Köhler G; Hecker D
    Oncology (Williston Park); 1997 Apr; 11(4 Suppl 3):34-7. PubMed ID: 9144689
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Paclitaxel in a novel formulation containing less Cremophor EL as first-line therapy for advanced breast cancer: a phase II trial.
    Chao TC; Chu Z; Tseng LM; Chiou TJ; Hsieh RK; Wang WS; Yen CC; Yang MH; Hsiao LT; Liu JH; Chen PM
    Invest New Drugs; 2005 Mar; 23(2):171-7. PubMed ID: 15744594
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Toxicity profile and objective response of paclitaxel in metastatic breast cancer.
    Ansari TN; Mahmood A; Khattak BK; Rasul S; Syed AS
    J Coll Physicians Surg Pak; 2005 Apr; 15(4):200-3. PubMed ID: 15857589
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Phase I study of paclitaxel and epirubicin in patients with metastatic breast cancer: a preliminary report on safety.
    Catimel G; Spielmann M; Dieras V; Kayitalire L; Pouillart P; Guastalla JP; Soler-Michel P; Graffand N; Garet F; Dumortier A; Pellae-Cosset B; Chazard M
    Semin Oncol; 1996 Feb; 23(1 Suppl 1):24-7. PubMed ID: 8629032
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.